What is HC Wainwright’s Forecast for CMPX FY2024 Earnings?

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Stock analysts at HC Wainwright lifted their FY2024 earnings estimates for Compass Therapeutics in a research report issued on Tuesday, November 12th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.36) for the year, up from their previous forecast of ($0.42). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Compass Therapeutics’ Q4 2024 earnings at ($0.11) EPS, FY2025 earnings at ($0.33) EPS, FY2026 earnings at ($0.29) EPS and FY2027 earnings at $0.09 EPS.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03.

CMPX has been the topic of a number of other research reports. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Monday, September 16th. Wedbush restated an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a research note on Wednesday, August 7th.

Compass Therapeutics Price Performance

NASDAQ:CMPX opened at $1.59 on Friday. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.34. The company has a market capitalization of $218.77 million, a PE ratio of -4.30 and a beta of 0.92. The firm’s 50-day moving average price is $1.76 and its 200-day moving average price is $1.42.

Institutional Trading of Compass Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CMPX. Rovin Capital UT ADV purchased a new stake in shares of Compass Therapeutics during the third quarter valued at approximately $25,000. Intech Investment Management LLC purchased a new position in shares of Compass Therapeutics in the third quarter worth $30,000. Cubist Systematic Strategies LLC bought a new position in Compass Therapeutics during the 2nd quarter valued at about $41,000. Panagora Asset Management Inc. purchased a new stake in shares of Compass Therapeutics during the 2nd quarter valued at about $68,000. Finally, SG Americas Securities LLC grew its stake in shares of Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after acquiring an additional 5,515 shares during the period. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.